| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.0021 | 0.9 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.0022 | 0.9 |